←
CURE Today32,964 posts
CURE Today avatar✓

CURE Today ✓

@cure_today

Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.

◷ Joined February 2009▧ 7,329 Photos and videos
CURE Today avatar
CURE Today@cure_today·18h

The FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated ALK-positive non-small cell lung cancer. In the ALKOVE-1 trial, 49% of patients previously treated with Alecensa (alectinib) responded. hubs.li/Q04FyX2j0

Post attachment
CURE Today avatar
CURE Today@cure_today·22h

Two Extraordinary Healers, one message 💛 2025 finalist Kathleen Coughlin: “Nursing is not just what I do, it is who I am.” 2024 winner Meaghan Mooney: “Impact takes many forms.” Nominate an oncology nurse by Dec. 9 👉 hubs.li/Q04FqFSb0 #ExtraordinaryHealer #OncNurse

0:24
CURE Today avatar
CURE Today@cure_today·Nov 16

Wilserdly (giredestrant) plus everolimus is now FDA approved for ESR1-mutated advanced breast cancer, after a 62% lower risk of cancer growth or death in the evERA trial. hubs.li/Q04Fqxc70

Post attachment
CURE Today avatar
CURE Today@cure_today·Nov 16

🚩 Red flag or green flag? ✅ Former NFL linebacker and lung cancer advocate @chrisdraft weighs in on what helps (and what doesn't) when supporting someone through cancer care. Sometimes, the little things are the biggest green flags! 💚 #LungCancerAwarenessMonth

1:46
CURE Today avatar
CURE Today@cure_today·Nov 13

🚩 Red flag or green flag? ✅ Lung cancer advocate and former NFL linebacker @chrisdraft weighs in on what helps or hurts at diagnosis and in the care that follows. What’s one green flag you’ve seen in cancer care? 💬 #LungCancerAwarenessMonth

1:31
CURE Today avatar
CURE Today@cure_today·Nov 13

FDA approves perioperative durvalumab + enfortumab vedotin for cisplatin-ineligible MIBC. VOLGA vs cystectomy alone: - EFS HR 0.51 (median NR vs 12.1 mo) - OS HR 0.58 A new option for patients who can’t get cisplatin. #BladderCancer #OncX

Post attachment
CURE Today avatar
CURE Today@cure_today·Nov 12

Former NFL linebacker @chrisdraft honors his wife, LaKeasha, through lung cancer advocacy. He joined CURE® with a message for people living with lung cancer and their loved ones. 🤍 Stay tuned for more from Chris on CURE®! #LungCancerAwarenessMonth

0:23
CURE Today avatar
CURE Today@cure_today·Nov 12

Managing multiple myeloma means managing symptoms and treatment side effects, too. Join a free webinar by @themmrf where experts share practical strategies for both, plus how to talk with your care team. Wed, Nov 18 | 6:30 PM ET Register: hubs.li/Q04DXBzB0

Post attachment
CURE Today avatar
CURE Today@cure_today·Nov 6

FDA grants accelerated approval to Rybrevant Faspro for advanced head and neck cancer after chemo and immunotherapy. In the OrigAMI-4 trial, 42% of patients saw their tumors shrink or disappear. hubs.li/Q04DBs8c0

Post attachment
CURE Today avatar
CURE Today@cure_today·Oct 26

FDA approves talazoparib + enzalutamide for metastatic hormone-sensitive prostate cancer with HRR gene mutations, based on TALAPRO-3 (rPFS HR 0.48; OS immature). Full story: hubs.li/Q04CkbMM0

Post attachment
CURE Today avatar
CURE Today@cure_today·Oct 22

FDA grants full approval to Keytruda for TMB-high solid tumors, but raises the cutoff to ≥13 mutations/megabase (from 10). In KEYNOTE-158, 36% of patients responded. What it means for patients: hubs.li/Q04C490d0

Post attachment
CURE Today avatar
CURE Today@cure_today·Oct 20

What does it mean to be “cured” of multiple myeloma? For the first time, experts have defined exactly that. Explore what this milestone means for patients in the latest issue of @themmrf Accelerator: hubs.li/Q04BxFMy0

Post attachment
CURE Today avatar
CURE Today@cure_today·Oct 20

Will you be in New Orleans? Make plans for an extraordinary evening! Join CURE® & @BloodCancerUtd on Dec. 11 for Extraordinary Honors in Blood Cancer, celebrating the people making a difference across the blood cancer community.  🎟️ Register: hubs.li/Q04BMmJz0

Post attachment